Optimized DNA sequence encoding extracellular domain of human IL-6 receptor (CD126) including a C-terminal 6His tag was expressed in HEK293 cells.
Recombinant IL-6 receptor (CD126) is a monomer protein consisting of 357 amino acid residue subunits, due to glycosylation migrates as an approximately 60-65 kDa protein on SDS-PAGE.
>97%, as determined by SDS-PAGE and HPLC
Recombinant IL-6R (CD126) activity was determined by its ability to enhance the IL6 activity on M1 mouse myeloid leukemia cells. The ED50 for this effect is typically 20-80 ng/ml.
Endotoxin content was assayed using a LAL gel clot method.
Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
Recombinant Human Interleukin-6 receptor (CD126) is supplied as a 0.2 μm filtered PBS solution, pH7.2.
Recombinant human IL-6R, as supplied, can be stored in working aliquots at 2° - 8° C for one month, or at -20°C to -70°C for twelve months.
Avoid repeated freeze/thaw cycles.
This product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
The effects of IL-6 are
mediated by a functional IL-
6 receptor (IL-6R), which
consists in a heterodimer
formed by an IL-6-binding α
chain (IL-6Rα) and a signal-
transducing subunit, gp130
or IL-6Rβ. Binding of IL-6
to the IL-6Rα induces
homodimerization of two
gp130 molecules, leading to
anti-inflammatory effect of IL-6 receptor blockade on experimental corneal alkali burn
Invest. Ophthalmol. Vis. Sci.,
exposure-response relationship of tocilizumab, an anti–IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis
J. Clin. Pharmacol.,
impact of IL-6 receptor inhibition on human memory b cells in vivo: impaired somatic hypermutation in preswitch memory b cells and modulation of mutational targeting in memory b cells
Ann Rheum Dis,
1507 - 1510.
species specificity of adam10 and adam17 proteins in interleukin-6 (il-6) trans-signaling and novel role of adam10 in inducible IL-6 receptor shedding
J. Biol. Chem.,
14804 - 14811.
anti-IL-6 receptor antibody (tocilizumab): a b cell targeting therapy
Ann Rheum Dis,
A57 - A58.